|
| PHOSPHATIDYLETHANOLAMINE Basic information |
Product Name: | PHOSPHATIDYLETHANOLAMINE | Synonyms: | 1,2-DIACYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE TYPE II-S SHEEP BRAIN;3-SN-PHOSPHATIDYLETHANOLAMINE;3-SN-PHOSPHATIDYLETHANOLAMINE, EGG YOLK;3-sn-phosphatidylethanolaminesolutionfrombovinebrain;Cephalin(fromsheepbrain);L-A-phosphatidylethanolamine type ii-S*commercial;Cephalins, brain;L-A-PHOSPHATIDYLETHANOLAMINE TYPE II-S*C OMMERCIAL G | CAS: | 90989-93-8 | MF: | C9H18NO8P | MW: | 299.214881 | EINECS: | 292-752-3 | Product Categories: | | Mol File: | 90989-93-8.mol |  |
| PHOSPHATIDYLETHANOLAMINE Chemical Properties |
storage temp. | -20°C | solubility | Chloroform: Soluble | form | solution | color | Light yellow to yellow | InChI | InChI=1S/C9H18NO8P/c1-7(11)15-5-9(18-8(2)12)6-17-19(13,14)16-4-3-10/h9H,3-6,10H2,1-2H3,(H,13,14) | InChIKey | CFWRDBDJAOHXSH-UHFFFAOYSA-N | SMILES | P(=O)(O[H])(OC([H])([H])C([H])([H])N([H])[H])OC([H])([H])C([H])(C([H])([H])OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O | CAS DataBase Reference | 90989-93-8 |
| PHOSPHATIDYLETHANOLAMINE Usage And Synthesis |
Uses | 1,2-Diacyl-sn-glycero-3-phosphoethanolamine is the major structural phopholipids in brain. | Biochem/physiol Actions | The major structural phospholipid in brain, comprising 20-25% of total lipid; primarily localized to gray matter. | in vivo | Phosphatidylethanolamine (375 mg/kg; i.p.) significantly inhibits food intake and locomotor activity in mice[4].
Phosphatidylethanolamine (2 g added to the basal diet containing 8 g of soybean oil; p.o.; dietary administration; ad libitum; 15-18 days) causes a decrease in serum cholesterol, phospholipid, apolipoprotein A-I (apoA-I) and apoE, an increase in high molecular weight apoB, alters the distribution of hepatic phospholipids and the fatty acid composition of serum and hepatic phospholipids in rats[6].
Animal Model: | Model: Male Wistar rats (weight: 143 g, specific age not mentioned) fed cholesterol-free semipurified diet[6] | Dosage: | 2 g of Phosphatidylethanolamine added to the basal diet containing 8 g of soybean oil | Administration: | Dietary administration, ad libitum, 15-18 days | Result: | Led to a significant decrease in serum cholesteryl ester, phospholipid, apoA-I and apoE, while serum apoB was higher compared to the PC and control groups.
Decreased hepatic cholesterol.
Altered the relative distribution of phospholipid subclasses in the liver.
Altered the fatty acid composition of liver PC and PE.
Enhanced the excretion of fecal neutral steroids.
Showed higher hepatic HMG-CoA reductase activity.
|
|
| PHOSPHATIDYLETHANOLAMINE Preparation Products And Raw materials |
|